Seroepidemiological Reconstruction of Long-term Chikungunya Virus Circulation in Burkina Faso and Gabon.


Journal

The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675

Informations de publication

Date de publication:
11 01 2023
Historique:
received: 29 03 2022
accepted: 13 06 2022
pubmed: 18 6 2022
medline: 14 1 2023
entrez: 17 6 2022
Statut: ppublish

Résumé

Chikungunya virus (CHIKV) is a major public health concern worldwide. However, infection levels are rarely known, especially in Africa. We recruited individuals from Ouagadougou, Burkina Faso and Lambaréné, Gabon (age range, 1-55 years), tested their blood for CHIKV antibodies, and used serocatalytic models to reconstruct epidemiological histories. In Ouagadougou, 291 of 999 (29.1%) individuals were seropositive, ranging from 2% among those aged <10 years to 66% in those aged 40-55 years. We estimated there were 7 outbreaks since the 1970s but none since 2001, resulting in 600 000 infections in the city, none of which were reported. However, we could not definitively conclude whether infections were due to CHIKV or o'nyong-nyong, another alphavirus. In Lambaréné, 117 of 427 (27%) participants were seropositive. Our model identified a single outbreak sometime since 2007, consistent with the only reported CHIKV outbreak in the country. These findings suggest sporadic outbreaks in these settings and that the burden remains undetected or incorrectly attributed.

Identifiants

pubmed: 35710849
pii: 6609553
doi: 10.1093/infdis/jiac246
pmc: PMC9833428
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

261-267

Subventions

Organisme : European Research Council
Pays : International
Organisme : Bill & Melinda Gates Foundation
Pays : United States
Organisme : NIH HHS
Pays : United States
Organisme : NIAID NIH HHS
ID : R24 AI120942
Pays : United States

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

Déclaration de conflit d'intérêts

Potential conflicts of interest. H. S. reports being a paid consultant to Gavi, the Vaccine Alliance, for work understanding the potential of chikungunya vaccines. All other authors report no potential conflicts. Funding to pay the Open Access publication charges for this article was provided by the University of Cambridge. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Références

Pathog Glob Health. 2018 Jun;112(4):182-194
pubmed: 29806537
Annu Rev Entomol. 2020 Jan 7;65:313-332
pubmed: 31594410
J Theor Biol. 2013 Feb 7;318:129-39
pubmed: 23154189
PLoS Negl Trop Dis. 2019 Mar 28;13(3):e0007213
pubmed: 30921321
PLoS One. 2018 Nov 29;13(11):e0207554
pubmed: 30496207
J Gen Virol. 2000 Feb;81(Pt 2):471-9
pubmed: 10644846
Proc Natl Acad Sci U S A. 2011 May 10;108(19):7872-7
pubmed: 21518887
Lancet. 2012 Feb 18;379(9816):662-71
pubmed: 22100854
Elife. 2019 Apr 08;8:
pubmed: 30958263
Biomed Res Int. 2015;2015:678084
pubmed: 26457301
J Infect Dis. 2016 Dec 15;214(suppl 5):S436-S440
pubmed: 27920169
PLoS Negl Trop Dis. 2012;6(2):e1517
pubmed: 22348166
J Hist Med Allied Sci. 1971 Jul;26(3):243-62
pubmed: 4938938
J Infect Dis. 2019 Nov 6;220(12):1915-1925
pubmed: 31418012
Expert Rev Vaccines. 2012 Sep;11(9):1087-101
pubmed: 23151166
J Infect Dis. 2016 Feb 15;213(4):604-10
pubmed: 26410592
Proc Natl Acad Sci U S A. 2016 Nov 22;113(47):13420-13425
pubmed: 27821727
Int J Infect Dis. 2021 Nov;112:1-7
pubmed: 34492392
Int J Infect Dis. 2020 Jun;95:167-173
pubmed: 32247051
Res Virol. 1995 Jan-Feb;146(1):69-73
pubmed: 7754238
PLoS One. 2013 Dec 02;8(12):e82259
pubmed: 24312651
Vector Borne Zoonotic Dis. 2015 Apr;15(4):223-30
pubmed: 25897809
Pathog Glob Health. 2017 Sep;111(6):271-275
pubmed: 28829253
Emerg Infect Dis. 2016 Jan;22(1):92-5
pubmed: 26690000
Antiviral Res. 2019 Jun;166:66-81
pubmed: 30905821
Nat Commun. 2021 Nov 18;12(1):6735
pubmed: 34795213
PLoS Negl Trop Dis. 2019 Dec 6;13(12):e0007882
pubmed: 31809504
Science. 2016 Jul 22;353(6297):353-4
pubmed: 27417493
PLoS Negl Trop Dis. 2019 Aug 23;13(8):e0007649
pubmed: 31442225

Auteurs

Jacqueline Kyungah Lim (JK)

International Vaccine Institute, Seoul, Republic of Korea.

Valery Ridde (V)

Montreal School of Public Health, Montreal, Quebec, Canada.

Selidji Todagbe Agnandji (ST)

Centre de Recherches Médicales de Lambaréné, Campus Centre de Recherches Médicales de Lambaréné, Lambaréné, Gabon.
Institute of Tropical Medicine, University of Tübingen, Tübingen, Germany.
German Centre for Infection Research, Partner Site Tübingen, Tübingen, Germany.
Centre de Recherches Médicales de Lambaréné, Lambaréné, Gabon.

Bertrand Lell (B)

Centre de Recherches Médicales de Lambaréné, Campus Centre de Recherches Médicales de Lambaréné, Lambaréné, Gabon.
Department of Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Vienna, Austria.

Seydou Yaro (S)

Centre Muraz, Bobo-Dioulasso, Burkina Faso.

Jae Seung Yang (JS)

International Vaccine Institute, Seoul, Republic of Korea.

Damien Hoinard (D)

Institut Pasteur, Paris, France.

Scott C Weaver (SC)

World Reference Center for Emerging Viruses and Arboviruses and Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA.

Jessica Vanhomwegen (J)

Institut Pasteur, Paris, France.

Henrik Salje (H)

Department of Genetics, University of Cambridge, Cambridge, United Kingdom.

In-Kyu Yoon (IK)

International Vaccine Institute, Seoul, Republic of Korea.
Coalition for Epidemic Preparedness Innovations, Washington, District of Columbia, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH